MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

AstraZeneca PLC ADR

Închisă

72.26 -0.37

Rezumat

Modificarea prețului

24h

Curent

Minim

72.03

Maxim

72.8

Indicatori cheie

By Trading Economics

Venit

-162M

1.7B

Vânzări

1.3B

15B

P/E

Medie Sector

32.667

63.778

EPS

1.045

Randament dividend

2.11

Marjă de profit

11.188

Angajați

94,300

EBITDA

330M

4.4B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+28.35% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.11%

2.39%

Statistici piață

By TradingEconomics

Capitalizare de piață

228B

Deschiderea anterioară

72.63

Închiderea anterioară

72.26

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

AstraZeneca PLC ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 mar. 2025, 03:15 UTC

Principalele dinamici ale pieței

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mar. 2025, 07:42 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

6 feb. 2025, 11:07 UTC

Câștiguri

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

31 mar. 2025, 09:31 UTC

Acțiuni populare

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17 mar. 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mar. 2025, 13:55 UTC

Market Talk
Achiziții, Fuziuni, Preluări

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mar. 2025, 07:04 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mar. 2025, 07:03 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mar. 2025, 07:03 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mar. 2025, 07:01 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mar. 2025, 07:01 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca Buying EsoBiotec for up to $1B

17 mar. 2025, 07:01 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mar. 2025, 07:00 UTC

Achiziții, Fuziuni, Preluări

AstraZeneca to Buy EsoBiotec

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb. 2025, 14:59 UTC

Market Talk

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 feb. 2025, 08:04 UTC

Market Talk
Câștiguri

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 feb. 2025, 11:34 UTC

Achiziții, Fuziuni, Preluări

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb. 2025, 11:34 UTC

Achiziții, Fuziuni, Preluări

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb. 2025, 11:33 UTC

Achiziții, Fuziuni, Preluări

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb. 2025, 11:33 UTC

Achiziții, Fuziuni, Preluări

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb. 2025, 11:31 UTC

Achiziții, Fuziuni, Preluări

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb. 2025, 11:30 UTC

Achiziții, Fuziuni, Preluări

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 feb. 2025, 10:49 UTC

Market Talk
Câștiguri

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 feb. 2025, 10:30 UTC

Top știri

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb. 2025, 15:18 UTC

Market Talk

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 feb. 2025, 13:24 UTC

Market Talk

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 feb. 2025, 12:01 UTC

Câștiguri

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 feb. 2025, 11:22 UTC

Market Talk
Câștiguri

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

6 feb. 2025, 11:18 UTC

Market Talk
Câștiguri

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

6 feb. 2025, 11:02 UTC

Market Talk
Câștiguri

AstraZeneca's China Woes Seem Manageable -- Market Talk

Comparație

Modificare preț

AstraZeneca PLC ADR Așteptări

Obiectiv de preț

By TipRanks

28.35% sus

Prognoză pe 12 luni

Medie 93.18 USD  28.35%

Maxim 98 USD

Minim 88 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAstraZeneca PLC ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

72.18 / 73.68Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.